Workflow
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Tops Revenue Estimates
CLSDClearside Biomedical(CLSD) ZACKS·2025-05-14 22:35

Core Insights - Clearside Biomedical, Inc. reported a quarterly loss of 0.11pershare,whichwasbetterthantheZacksConsensusEstimateofalossof0.11 per share, which was better than the Zacks Consensus Estimate of a loss of 0.12, and an improvement from a loss of 0.17pershareayearago[1]−Thecompanyachievedrevenuesof0.17 per share a year ago [1] - The company achieved revenues of 2.33 million for the quarter ended March 2025, significantly surpassing the Zacks Consensus Estimate by 785.93%, compared to revenues of 0.23millioninthesamequarterlastyear[2]−Thestockhasunderperformedthemarket,losingabout5.30.23 million in the same quarter last year [2] - The stock has underperformed the market, losing about 5.3% since the beginning of the year, while the S&P 500 gained 0.1% [3] Financial Performance - Over the last four quarters, Clearside Biomedical has exceeded consensus EPS estimates four times and topped consensus revenue estimates three times [2] - The current consensus EPS estimate for the upcoming quarter is -0.12 on revenues of 0.26million,andforthecurrentfiscalyear,itis−0.26 million, and for the current fiscal year, it is -0.45 on revenues of $1.19 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Clearside Biomedical belongs, is currently ranked in the top 30% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Clearside Biomedical's stock performance [5]